Healthy Lipid Support

Poly-Chol Red  

NC609 

120 Capsules  Suggested Dosage: As a dietary supplement, adults take 2 capsules 2 times daily or as directed by a health care professional.

red rice yeast------------------------------------------------------------------------------------------------------------ 800 mg  

policosanol---------------------------------------------------------------------------------------------------------------- 6 mg

Other Ingredient: Rice Flour

This statement has not been evaluated by the FDA. This product is not intended to diagnose, treat, cure or prevent any disease.

References

Fernandez L, et al. Policosanol: results of a postmarketing surveillance study of 27,879 patients. Curr Ther Res 1998;59:717-22.

Pons P, et al. Effect of successive dose increases of policosanol on the lipid profile of patients with type II hypercholesterolemia and tolerability to treatment. Int J Clin Pharmacol Res 1994;14:27-33.

Aneiros EM, et al. Effect of policosanol in lowering cholesterol levels in patients with type II hypercholesterolemia. Curr Ther Res 1995;56:176-82.

Castafio G, et al. One-year study of the efficacy and safety of policosanol (5 mg twice daily) in the treatment of type II hypercholesterolemia. Curr Ther Res 1995;56:296-304.

Canetti M, et al. A two-year study on the efficacy and tolerability of policosanol in patients with type II hyperlipoproteinemia. Int J Clin Pharmacol Res 1995;15:159-65.

Mas R, et al. Effects of policosanol in patients with type II hypercholesterolemia and additional coronary risk factors. Clin Pharmacol Ther 1998;65:439-47.

Torres O, et al. Treatment of hypercholesterolemia in noninsulin-dependent diabetes mellitus (NIDDM) with policosanol. Diabetes Care 1997;18:393-7.

Fernandez JC, et al. Comparison of the efficacy, safety and tolerability of policosanol versus fluvastatin in elderly hypercholesterolaemic women. Clin Drug Invest 2001;21:103-13.

Castano G, et al. Efficacy and tolerability of policosanol compared with lovastatin in patients with type II hypercholesterolemia and concomitant coronary risk factors. Curr Ther Res 2000;61:137-46.

Castano G, et al. A long-term study of policosanol in the treatment of intermittent claudication. Angiology 2001;52:115-25.

Gouni-Berthold I, Berthold HK. Policosanol: Clinical pharmacology and therapeutic significance of a new lipid-lowering agent. Am Heart J 2002;143:356-365.

Mas R, Castano G, Illnait J, Fernandez L, Fernandez J, Aleman C, Pontigas V, Lescay M. Effects of policosanol in patients with type II hypercholesterolemia and additional coronary risk factors. Clin Pharmacol Ther 1999;65:439-437.

Menendez R, Fernandez SI, Del Rio A, Gonzalez RM, Fraga V, Amor AM, Mas RM. Policosanol inhibits cholesterol biosynthesis and enhances low density lipoprotein processing in cultured human fibroblasts. Biol Res 1994;27: 199-203.

Menendez R, Mas R, Amor AM, Gonzalez RM, Fernandez JC, Rodeiro I, Zayas M, Jimenez S. Effects of policosanol treatment on the susceptibility of low density lipoprotein (LDL) isolated from healthy volunteers to oxidative modification in vitro. Br J Clin Pharmacol 2000;50:255-262.

Noa M, Mas R, Mesa R. Effect of policosanol on intimal thickening in rabbit cuffed carotid artery. Int J Cardiol 1998;67:124-32.